NCT00480181View on ClinicalTrials.gov

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Neuropathic PainMultiple Sclerosis
Interventions
DRUG

nabilone

Cesamet (nabilone) capsules given at titrating dosages as per protocol.

OTHER

placebo

placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.

Trial Locations (1)

R3A 1R9

Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

University of Manitoba

OTHER

NCT00480181 - Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis | Biotech Hunter | Biotech Hunter